Zobrazeno 1 - 10
of 214
pro vyhledávání: '"Bertrand Routy"'
Autor:
Léa Montégut, Peng Liu, Liwei Zhao, María Pérez-Lanzón, Hui Chen, Misha Mao, Shuai Zhang, Lisa Derosa, Julie Le Naour, Flavia Lambertucci, Silvia Mingoia, Uxía Nogueira-Recalde, Rafael Mena-Osuna, Irene Herranz-Montoya, Nabil Djouder, Sylvain Baulande, Hui Pan, Adrien Joseph, Meriem Messaoudene, Bertrand Routy, Marine Fidelle, Tarek Ben Ahmed, Olivier Caron, Pierre Busson, David Boulate, Mélanie Deschasaux-Tanguy, Nathalie Arnault, Jonathan G. Pol, Eliane Piaggio, Mathilde Touvier, Laurence Zitvogel, Suzette Delaloge, Isabelle Martins, Guido Kroemer
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-19 (2024)
Abstract Background The plasma concentrations of acyl coenzyme A binding protein (ACBP, also known as diazepam-binding inhibitor, DBI, or ‘endozepine’) increase with age and obesity, two parameters that are also amongst the most important risk fa
Externí odkaz:
https://doaj.org/article/10c82ea6861a4e7ebedd7680b9b488ac
Autor:
Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M. Vanderbilt, Pooja Gogia, Antoine Desilets, Meriem Messaoudene, Daniel Kelly, Marc Ladanyi, Matthew D. Hellmann, Laurence Zitvogel, Charles M. Rudin, Bertrand Routy, Lisa Derosa, Adam J. Schoenfeld
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of antibiotics on clinical o
Externí odkaz:
https://doaj.org/article/6b78137517bb4690816d94fa12584591
Autor:
Jesse Papenburg, Bertrand Routy, Todd C Lee, Matthew P Cheng, Hao Shi, Cedric P Yansouni, Alexander Lawandi, Connor Prosty, Khaled Katergi, Philip Burnham, Lee Swem
Publikováno v:
eGastroenterology, Vol 2, Iss 3 (2024)
Composed of an elaborate ecosystem of bacteria, fungi, viruses and protozoa residing in the human digestive tract, the gut microbiome influences metabolism, immune modulation, bile acid homeostasis and host defence. Through observational and preclini
Externí odkaz:
https://doaj.org/article/3af652e3d0874a70ad5c21db3f0b1e33
Autor:
Carolina Alves Costa Silva, Gianmarco Piccinno, Déborah Suissa, Mélanie Bourgin, Gerty Schreibelt, Sylvère Durand, Roxanne Birebent, Marine Fidelle, Cissé Sow, Fanny Aprahamian, Paolo Manghi, Michal Punčochář, Francesco Asnicar, Federica Pinto, Federica Armanini, Safae Terrisse, Bertrand Routy, Damien Drubay, Alexander M. M. Eggermont, Guido Kroemer, Nicola Segata, Laurence Zitvogel, Lisa Derosa, Kalijn F. Bol, I. Jolanda M. de Vries
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Tumor immunosurveillance plays a major role in melanoma, prompting the development of immunotherapy strategies. The gut microbiota composition, influencing peripheral and tumoral immune tonus, earned its credentials among predictors of survi
Externí odkaz:
https://doaj.org/article/93008ed84ad54d8ba4a63ee21aaebb08
Autor:
Léa Montégut, Lisa Derosa, Meriem Messaoudene, Hui Chen, Flavia Lambertucci, Bertrand Routy, Laurence Zitvogel, Isabelle Martins, Guido Kroemer
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Acyl CoA binding protein (ACBP, which is encoded by diazepam binding inhibitor, DBI) acts on the gamma-amino butyric acid (GABA) receptor type A via a specific binding site that is shared by diazepam and other benzodiazepines. Both ACBP/DBI and benzo
Externí odkaz:
https://doaj.org/article/480b3a1c26644ef7a0ffca92154e1d50
Autor:
Marius Bredon, Camille Danne, Hang Phuong Pham, Pauline Ruffié, Alban Bessede, Nathalie Rolhion, Laura Creusot, Loic Brot, Iria Alonso, Philippe Langella, Lisa Derosa, Alexis B. Cortot, Bertrand Routy, Laurence Zitvogel, Nicola Segata, Harry Sokol
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Gut microbiota impacts responses to immune checkpoint inhibitors (ICI). A high level of Faecalibacterium prausnitzii have been associated with a positive response to ICI in multiple cancer types. Here, based on fecal shotgun metagenomics data, we sho
Externí odkaz:
https://doaj.org/article/7abd8125d14548dca241b6f3a7e8841e
Autor:
Sevinj Yolchuyeva, Leyla Ebrahimpour, Marion Tonneau, Fabien Lamaze, Michele Orain, François Coulombe, Julie Malo, Wiam Belkaid, Bertrand Routy, Philippe Joubert, Venkata SK. Manem
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising first-line therapeutics in the management of non-small cell lung cancer (NSCLC). However, only a subset of these patients responds to ICIs, highlighting
Externí odkaz:
https://doaj.org/article/402d9860876a4dd9abb12bb7bde2e5fb
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9406-9427 (2023)
The gastrointestinal microbiome has been shown to play a key role in determining the responses to cancer immunotherapy, including immune checkpoint inhibitor (ICI) therapy and CAR-T. In patients with non-small cell lung cancer (NSCLC), increasing evi
Externí odkaz:
https://doaj.org/article/b0c9d34436d546139dd39a000520dbbf
Autor:
Sevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, Fabien Lamaze, Michele Orain, François Coulombe, Julie Malo, Wiam Belkaid, Bertrand Routy, Philippe Joubert, Venkata S. K. Manem
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract With the increasing use of immune checkpoint inhibitors (ICIs), there is an urgent need to identify biomarkers to stratify responders and non-responders using programmed death-ligand (PD-L1) expression, and to predict patient-specific outcom
Externí odkaz:
https://doaj.org/article/fd7837095cb744958b685f0602f90ba3
Autor:
Sevinj Yolchuyeva, PhD, Elena Giacomazzi, MSc, Marion Tonneau, PhD, Fabien Lamaze, PhD, Michele Orain, MT, François Coulombe, MD, Julie Malo, CCRP, Wiam Belkaid, PhD, Bertrand Routy, MD, PhD, Philippe Joubert, MD, PhD, Venkata S.K. Manem, MSc, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100602- (2023)
Background: Although the immune checkpoint inhibitors, nivolumab and pembrolizumab, were found to be promising in patients with advanced NSCLC, some of them either do not respond or have recurrence after an initial response. It is still unclear who w
Externí odkaz:
https://doaj.org/article/c5741ef7957448d1a093b10a06ccf5fe